Dilution profile // every instrument, one screen, from SEC filings

Korsana Biosciences, Inc. (KRSA)

CIK 1755237 · all EDGAR filings →

Overall dilution risk
HIGHworst of 3 computed sub-ratings (offering ability)
= the worst band among the computed sub-ratings, no hidden weighting
not every sub-rating was computable; treat as a floor
Offering ability
HIGHS-3 on file 2025-05-06
= is there a registration (S-1/S-3 family) on file without a later withdrawal
no structured fee data on the live registrations, so this is a yes/no, not a size
Overhead supply
NOT COMPUTEDno warrant count tagged in XBRL
= warrant shares outstanding divided by current shares outstanding
absence of a tag is not proof of absence of warrants
Historical dilution
HIGH+1763% O/S in 3y
= share count now vs 3 years ago (bands: 30% / 100%); a reverse split pushes this negative
a reverse-split-sized cliff is in this window; read the chart
Cash need
LOW~1652 months of runway
= cash vs trailing operating burn (bands: 6mo / 24mo; positive operating CF = low)
the company itself flagged going-concern doubt

Same rating bands the category standard uses, but free, with the formula on the chip and the gaps in the data said out loud.

Shares outstanding over time

2021-02-182026-11-02

Latest: 45.5M shares as of Nov 2, 2026 (10-Q).

⊙
EVIDENCE — filed/published fact
SourceSEC XBRL, cover-page share count
Fielddei:EntityCommonStockSharesOutstanding
As of2026-11-02
HowThe newest cover-page count as filed. It is used as the current count only while it is no more than about 15 months older than the company’s newest periodic filing; the float checker applies a 200-day rule and sets it beside the balance-sheet count.
Open the source document →
Share count fell from 43.5M to 2.4M between May 1, 2023 and Jul 24, 2023, a pattern consistent with a reverse split (roughly 1-for-18); simultaneous issuance can skew the raw ratio, so confirm in the filings. The red bar marks the cliff.

Cash runway

Going-concern warning

auditor flagged substantial doubt

The company itself flagged going-concern doubt in a filing.

Full breakdown: cash runway tool · source filing →

Warrants

TrancheWarrantsExercise priceTermNotes
Pre-Funded Warrants20.2M$2.3647——
Exchange Rationot tagged$11.4016——

Tranches exactly as the company dimensioned them in its 10-Q filed Nov 5, 2026 →. Groupings can overlap (a “Series E and F” row is not additive with a “Series E” row), so do not sum this column. A tranche the filer did not tag is absent here, not absent from the cap table. DOWN-ROUND = the filer tagged price-protection accounting scoped to that tranche.

No warrant figures tagged in this filer’s XBRL facts. That means the company has not reported them in structured form; it does not prove no warrants exist. The exhibits are the ground truth.

Convertible notes

No convertible-note facts tagged in the 10-Q filed Nov 5, 2026. If convertible notes exist, their terms live in exhibit prose for this filer and are not parsed; absence of a tag is not proof of absence. The exhibits are the ground truth.

Fully diluted build-up

Shares outstanding plus every potential-share instrument the filer tagged in XBRL, each at its own as-of date. An estimate assembled from filed figures, not a filing figure itself.

Shares outstanding45.5MNov 2, 2026
+ Pre-Funded Warrants (if exercised)20.2MSep 30, 2026
Fully diluted estimate65.7M+44.3% vs O/S

Still excluded, because the filer does not tag them in countable form: employee options and RSUs, any instrument living only in exhibit prose, and instruments above missing a share count. Inputs carry different as-of dates, shown per row. Each figure traces to the tranche and note tables above and their cited filings.

Registrations and offerings

S-3May 6, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →
S-3Feb 4, 2025no structured fee exhibit in this filing (predates fee-data XBRL or fee deferred)filing →

Last 12 months: 1 executed · 0 registered.

EXECUTEDSep 11, 2026Unregistered share sale disclosed (8-K item 3.02)8-K →
UPDATEJul 24, 2026Prospectus update — often a resale registration, not necessarily new capital424B3 →
EFFECTIVEJul 24, 2026SEC declared a registration effective — selling can beginEFFECT →
EFFECTIVEMay 15, 2025SEC declared a registration effective — selling can beginEFFECT →
EXECUTEDMay 7, 2025Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm)424B5 →
REGISTEREDMay 6, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDMar 25, 2025Unregistered share sale disclosed (8-K item 3.02)8-K →
EFFECTIVEFeb 12, 2025SEC declared a registration effective — selling can beginEFFECT →
REGISTEREDFeb 4, 2025S-3 registration — capacity to sell shares, not a sale yetS-3 →
EXECUTEDMay 25, 2023Unregistered share sale disclosed (8-K item 3.02)8-K →
EXECUTEDMay 12, 2023Unregistered share sale disclosed (8-K item 3.02)8-K →
EXECUTEDJun 24, 2021Final prospectus — offering priced (typical for IPOs and marketed share deals)424B4 →

Full history and shelf status: offering checker · S-3 shelf checker

Source: SEC EDGAR XBRL company facts and filing metadata, fetched live and cached briefly. Share counts are cover-page figures with their form named. Warrant tranches and convertible notes come from the dimensioned facts in the latest 10-Q/10-K instance document, exactly as the company tagged them; untagged tranches and notes are absent, not disproven. Nothing on this page is manually verified and nothing is behind a login: what free data supports is shown, what it cannot support is stated. Not investment advice.

Keep going: float checker · offering calendar · short-squeeze screener · full KRSA workspace

Free to use. No account, no card.